{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:04:44Z","timestamp":1794467084409,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to assess activity and safety of this triple combination in female patients with relapsed high-grade AOC following prior platinum-based therapy. Patients were treated with olaparib (300\u2009mg orally, twice daily), the bevacizumab biosimilar FKB238 (15\u2009mg\/kg intravenously, once-every-3-weeks), and durvalumab (1.12\u2009g intravenously, once-every-3-weeks) in nine French centers. The primary endpoint was the non-progression rate at 3 months for platinum-resistant relapse or 6 months for platinum-sensitive relapse per RECIST 1.1 and irRECIST. Secondary endpoints were CA-125 decline with CA-125 ELIMination rate constant K (KELIM-B) per CA-125 longitudinal kinetics over 100 days, progression free survival and overall survival, tumor response, and safety. Non-progression rates were 69.8% (90%CI 55.9%-80.0%) at 3 months for platinum-resistant relapse patients (N\u2009=\u200941), meeting the prespecified endpoint, and 43.8% (90%CI 29.0%-57.4%) at 6 months for platinum-sensitive relapse (N\u2009=\u200933), not meeting the prespecified endpoint. Median progression-free survival was 4.1 months (95%CI 3.5\u20135.9) and 4.9 months (95%CI 2.9\u20137.0) respectively. Favorable KELIM-B was associated with better survival. No toxic deaths or major safety signals were observed. Here we show that further investigation of this triple combination may be considered in AOC patients with platinum-resistant relapse.<\/jats:p>","DOI":"10.1038\/s41467-024-45974-w","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T03:02:22Z","timestamp":1709607742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6001-164X","authenticated-orcid":false,"given":"Gilles","family":"Freyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1078-8554","authenticated-orcid":false,"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Carrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Langlois-Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-5383","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Selle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Abdeddaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coraline","family":"Dubot-Poitelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-4777","authenticated-orcid":false,"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-0218","authenticated-orcid":false,"given":"Michele","family":"Lamuraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"45974_CR1","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann. Oncol. 24, vi24\u2013vi32 (2013).","journal-title":"Ann. Oncol."},{"key":"45974_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4498-z","volume":"18","author":"J-Y Lee","year":"2018","unstructured":"Lee, J.-Y. et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer 18, 601 (2018).","journal-title":"BMC Cancer"},{"key":"45974_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18, 779\u2013791 (2017).","journal-title":"Lancet Oncol."},{"key":"45974_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","volume":"22","author":"S Pignata","year":"2021","unstructured":"Pignata, S. et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 22, 267\u2013276 (2021).","journal-title":"Lancet Oncol."},{"key":"45974_CR5","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039\u20132045 (2012).","journal-title":"J. Clin. Oncol."},{"key":"45974_CR6","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302\u20131308 (2014).","journal-title":"J. Clin. Oncol."},{"key":"45974_CR7","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl J. Med."},{"key":"45974_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl J. Med."},{"key":"45974_CR9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann, J. A. et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 17, 1579\u20131589 (2016).","journal-title":"Lancet Oncol."},{"key":"45974_CR10","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284 (2017).","journal-title":"Lancet Oncol."},{"key":"45974_CR11","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1073\/pnas.0904783107","volume":"107","author":"DC Hegan","year":"2010","unstructured":"Hegan, D. C. et al. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl Acad. Sci. USA 107, 2201\u20132206 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45974_CR12","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert, E. J. et al. Combination of PARP inhibitor olaparib, and PD-L1 Inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin. Cancer Res 26, 4268\u20134279 (2020).","journal-title":"Clin. Cancer Res"},{"key":"45974_CR13","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.3390\/cancers13174438","volume":"13","author":"BA Maiorano","year":"2021","unstructured":"Maiorano, B. A., Maiorano, M. F. P., Lorusso, D. & Maiello, E. Ovarian cancer in the era of immune checkpoint inhibitors: state of the art and future perspectives. Cancers 13, 4438 (2021).","journal-title":"Cancers"},{"key":"45974_CR14","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588\u20135599 (2012).","journal-title":"Cancer Res"},{"key":"45974_CR15","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl J. Med."},{"key":"45974_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"45974_CR17","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1158\/1078-0432.CCR-15-2518","volume":"22","author":"IV Tiper","year":"2016","unstructured":"Tiper, I. V. et al. VEGF potentiates GD3-mediated immunosuppression by human ovarian cancer cells. Clin. Cancer Res. 22, 4249\u20134258 (2016).","journal-title":"Clin. Cancer Res."},{"key":"45974_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi, M. et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer 18, 60 (2019).","journal-title":"Mol. Cancer"},{"key":"45974_CR19","doi-asserted-by":"publisher","first-page":"S511","DOI":"10.1016\/j.annonc.2023.09.1925","volume":"34","author":"J-M Lee","year":"2023","unstructured":"Lee, J.-M. et al. Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023). Abstract 746MO. Ann. Oncol. 34, S511 (2023).","journal-title":"Ann. Oncol."},{"key":"45974_CR20","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034\u20131046 (2021).","journal-title":"Lancet Oncol."},{"key":"45974_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos, P. A. et al. single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 5, 1141\u20131149 (2019).","journal-title":"JAMA Oncol."},{"key":"45974_CR22","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","volume":"5","author":"JF Liu","year":"2019","unstructured":"Liu, J. F. et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol. 5, 1731\u20131738 (2019).","journal-title":"JAMA Oncol."},{"key":"45974_CR23","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis, U. A. et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J. Clin. Oncol. 41, 2436\u20132445 (2023).","journal-title":"J. Clin. Oncol."},{"key":"45974_CR24","doi-asserted-by":"crossref","unstructured":"Moore, K. N. et al. Phase III MIRASOL (GOG 3045\/ENGOT-ov55) study: initial report of mirvetuximab soravtansine vs. investigator\u2019s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. J. Clin. Oncol. 41, LBA5507\u2013LBA5507 (2023).","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507"},{"key":"45974_CR25","doi-asserted-by":"publisher","first-page":"S615","DOI":"10.1016\/j.annonc.2020.08.953","volume":"31","author":"Y Drew","year":"2020","unstructured":"Drew, Y. et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Abstract 814MO. Ann. Oncol. 31, S615\u2013S616 (2020).","journal-title":"Ann. Oncol."},{"key":"45974_CR26","doi-asserted-by":"publisher","first-page":"S1283","DOI":"10.1016\/j.annonc.2021.08.2110","volume":"32","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine, E. et al. LBA33 - Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase IIIb OReO\/ENGOT Ov-38 trial. Ann. Oncol. 32, S1283\u2013S1346 (2021).","journal-title":"Ann. Oncol."},{"key":"45974_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40829-2","volume":"14","author":"Y-N Kim","year":"2023","unstructured":"Kim, Y.-N. et al. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01\/APGOT-OV4. Nat. Commun. 14, 5476 (2023).","journal-title":"Nat. Commun."},{"key":"45974_CR28","doi-asserted-by":"publisher","first-page":"v485","DOI":"10.1093\/annonc\/mdz253.016","volume":"30","author":"Y Drew","year":"2019","unstructured":"Drew, Y. et al. Phase II study of olaparib + durvalumab (MEDIOLA): updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Ann. Oncol. 30, v485\u2013v486 (2019).","journal-title":"Ann. Oncol."},{"key":"45974_CR29","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-18-3335","volume":"25","author":"O Colomban","year":"2019","unstructured":"Colomban, O. et al. Early modeled longitudinal CA-125 kinetics and survival of ovarian cancer patients: a GINECO AGO MRC CTU study. Clin. Cancer Res. 25, 5342\u20135350 (2019).","journal-title":"Clin. Cancer Res."},{"key":"45974_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/cancers14010098","volume":"14","author":"A Lauby","year":"2021","unstructured":"Lauby, A. et al. The increasing prognostic and predictive roles of the tumor primary chemosensitivity assessed by CA-125 elimination rate constant K (KELIM) in ovarian cancer: a narrative review. Cancers 14, 98 (2021).","journal-title":"Cancers"},{"key":"45974_CR31","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1136\/ijgc-2019-001109","volume":"30","author":"E H\u00f8gdall","year":"2020","unstructured":"H\u00f8gdall, E. et al. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. Int. J. Gynecol. Cancer 30, 1034\u20131042 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"45974_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. et al. T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318\u2013327 (2019).","journal-title":"J. Clin. Oncol."},{"key":"45974_CR33","doi-asserted-by":"publisher","first-page":"e9615","DOI":"10.1371\/journal.pone.0009615","volume":"5","author":"K Yoshihara","year":"2010","unstructured":"Yoshihara, K. et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS ONE 5, e9615 (2010).","journal-title":"PLoS ONE"},{"key":"45974_CR34","doi-asserted-by":"publisher","first-page":"e003302","DOI":"10.1136\/jitc-2021-003302","volume":"10","author":"J Manitz","year":"2022","unstructured":"Manitz, J. et al. Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. J. Immunother. Cancer 10, e003302 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"45974_CR35","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","volume":"22","author":"BJ Monk","year":"2021","unstructured":"Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275\u20131289 (2021).","journal-title":"Lancet Oncol."},{"key":"45974_CR36","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J. Clin. Oncol. 39, 1842\u20131855 (2021).","journal-title":"J. Clin. Oncol."},{"key":"45974_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","volume":"7","author":"AS Zimmer","year":"2019","unstructured":"Zimmer, A. S. et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses. J. Immunother. Cancer 7, 197 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"45974_CR38","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1200\/JCO.2021.39.15_suppl.5504","volume":"39","author":"D O\u2019Malley","year":"2021","unstructured":"O\u2019Malley, D. et al. Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis. J. Clin. Oncol. 39, 5504\u20135504 (2021).","journal-title":"J. Clin. Oncol."},{"key":"45974_CR39","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.2021.39.15_suppl.5505","volume":"39","author":"SN Westin","year":"2021","unstructured":"Westin, S. N. et al. EFFORT: EFFicacy Of adavosertib in parp ResisTance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. J. Clin. Oncol. 39, 5505\u20135505 (2021).","journal-title":"J. Clin. Oncol."},{"key":"45974_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ygyno.2013.05.013","volume":"130","author":"B You","year":"2013","unstructured":"You, B. et al. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecol. Oncol. 130, 289\u2013294 (2013).","journal-title":"Gynecol. Oncol."},{"key":"45974_CR41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","volume":"64","author":"C Dartois","year":"2007","unstructured":"Dartois, C. et al. Overview of model-building strategies in population PK\/PD analyses: 2002-2004 literature survey. Br. J. Clin. Pharm. 64, 603\u2013612 (2007).","journal-title":"Br. J. Clin. Pharm."},{"key":"45974_CR42","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"45974_CR43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/sim.721","volume":"20","author":"RP A\u2019Hern","year":"2001","unstructured":"A\u2019Hern, R. P. Sample size tables for exact single-stage phase II designs. Stat. Med. 20, 859\u2013866 (2001).","journal-title":"Stat. Med."}],"updated-by":[{"DOI":"10.1038\/s41467-024-48915-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45974-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45974-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45974-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T03:03:11Z","timestamp":1717556591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45974-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45974"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45974-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"29 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-024-48915-9","URL":"https:\/\/doi.org\/10.1038\/s41467-024-48915-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<b>GF<\/b>: honoraria (AstraZeneca, MSD, BMS, Lilly, GSK, Seagen, Daiichi-Sankyo); <b>AF<\/b>: honoraria (AstraZeneca, GSK, Clovis), meeting support (AstraZeneca, GSK, Pharma Mar), leadership in other board (GSK); <b>OT<\/b>: honoraria (Roche, Pfizer, Novartis-Sandoz, Lilly, MSD, AstraZeneca, Pierre Fabre, Seagen, Daiichi-Sankyo, Gilead, Eisai, Menarini-Stemline), meeting support (Roche, Pfizer, Novartis-Sandoz, Lilly, MSD, AstraZeneca, Seagen, Daiichi-Sankyo, Gilead), consulting\/board (Roche, Pfizer, Novartis-Sandoz, Lilly, MSD, AstraZeneca, Pierre Fabre, Seagen, Daiichi-Sankyo, Gilead, Eisai); <b>FS<\/b>: consulting (AstraZeneca, MSD, GSK-Tesaro), honoraria (AstraZeneca, MSD, GSK-Tesaro), meeting support (AstraZeneca, MSD, GSK-Tesaro, Roche), <b>CA<\/b> grants (GSK), honoraria (GSK, Clovis Oncology, AstraZeneca), meeting support (GSK); <b>AL<\/b>: honoraria (AstraZeneca, GSK, Clovis), consulting\u00a0(AstraZeneca, GSK, Clovis, MSD, Merck Serono, Ability, Zentalis),funded research (AstraZeneca, GSK, Clovis, MSD, Ability, Agenus, Iovance, Sanofi, Roche, OSEimmuno, BMS); <b>MF<\/b>: honoraria (AstraZeneca, GSK), consulting\/board (AstraZeneca, GSK), <b>LG<\/b>: honoraria (AstraZeneca), meeting support (AstraZeneca). The remaining authors declare no competing interests (CL-J, CD, JL, AC, ML).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1985"}}